Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
458.05
+6.46 (1.43%)
At close: Mar 19, 2026, 4:00 PM EDT
457.43
-0.62 (-0.14%)
After-hours: Mar 19, 2026, 7:56 PM EDT
Vertex Pharmaceuticals Stock Forecast
Stock Price Forecast
The 26 analysts that cover Vertex Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $539.08, which forecasts a 17.69% increase in the stock price over the next year. The lowest target is $414 and the highest is $641.
Price Target: $539.08 (+17.69%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Vertex Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 7 | 8 | 8 | 10 |
| Buy | 8 | 8 | 9 | 12 | 12 | 12 |
| Hold | 10 | 10 | 8 | 7 | 7 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 26 | 26 | 24 | 27 | 27 | 29 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $575 | Hold → Strong Buy | Upgrades | $575 | +25.53% | Mar 18, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $490 → $525 | Strong Buy | Maintains | $490 → $525 | +14.62% | Mar 11, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $570 → $596 | Buy | Maintains | $570 → $596 | +30.12% | Mar 10, 2026 |
| B of A Securities | B of A Securities | Strong Buy Maintains $571 → $598 | Strong Buy | Maintains | $571 → $598 | +30.55% | Mar 10, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $575 → $585 | Strong Buy | Maintains | $575 → $585 | +27.72% | Mar 10, 2026 |
Financial Forecast
Revenue This Year
13.30B
from 12.00B
Increased by 10.79%
Revenue Next Year
14.64B
from 13.30B
Increased by 10.14%
EPS This Year
19.39
from 15.32
Increased by 26.54%
EPS Next Year
22.05
from 19.39
Increased by 13.72%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 13.9B | 17.2B | |||
| Avg | 13.3B | 14.6B | |||
| Low | 12.1B | 12.7B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 16.1% | 29.3% | |||
| Avg | 10.8% | 10.1% | |||
| Low | 0.5% | -4.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 22.16 | 28.14 | |||
| Avg | 19.39 | 22.05 | |||
| Low | 16.82 | 18.07 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 44.6% | 45.2% | |||
| Avg | 26.5% | 13.7% | |||
| Low | 9.8% | -6.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.